Immunogenicity and Safety of FluBlok Trivalent Recombinant Hemagglutinin Influenza Vaccine in Healthy Pediatrics
Clinical trial NCT00336453 · COMPLETED
Trial details
- NCT number
- NCT00336453
- Sponsor
- Protein Sciences Corporation
- Status
- COMPLETED
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2006-10-01
- Primary completion
- 2007-07-01
- Enrollment
- 156
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.